Skip to main content
SpringerLink
Log in

Perspectives of Comparative Effectiveness Research from the World of Decision Making

  • Chapter
  • First Online:
Decision Making in a World of Comparative Effectiveness Research

  • 895 Accesses

Abstract

Interest in comparative effectiveness research (CER) and reliance on CER for treatment selection and resource allocation decisions continues to grow. However, the goals of CER (i.e., to inform decision making by providing evidence on the effectiveness and consequences of treatment options) are often difficult to attain, and the pace of change in conducting and disseminating the results of CER has been frustratingly slow. This introduction to Decision Making in a World of Comparative Effectiveness Research surveys the wide range of viewpoints that reflect on various challenges facing both researchers conducting CER and healthcare decision makers. As a whole, the vision for CER expressed in this book is one that remains optimistic in achieving its goals, where real-world studies and big data analyses are applied to meet pragmatic needs of clinicians, patients, and policymakers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. CBO (2007) Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role (Rep. No. 2975). Congressional Budget Office, Washington https://www.cbo.gov/publication/41655. Accessed 11/13/2016

    Google Scholar 

  2. HHS/PCORI (2009) Federal coordinating council for comparative effectiveness research. Department of Health and Human Services, Washington, DC

    Google Scholar 

  3. IOM. (2009) Initial National priorities for comparative effectiveness research. http://www.nationalacademies.org/hmd/reports/2009/comparativeeffectivenessresearchpriorities.aspx. Accessed 11/13/2016

  4. AHRQ. (2015) What is Comparative Effectiveness Research. US Department of Health & Human Services. Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness-research1/. Accessed 11/13/2016

  5. GAO. (2015) Comparative Effectiveness Research: HHS Needs to Strengthen Dissemination and Data-Capacity-Building Efforts. United States Government Accountability Office. http://www.gao.gov/assets/670/668804.pdf. Accessed 11/13/2016

  6. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516. doi:10.1056/NEJMoa070829

    Article  CAS  PubMed  Google Scholar 

  7. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG (2008) Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes 1(1):12–20. doi:10.1161/circoutcomes.108.798462

    Article  PubMed  Google Scholar 

  8. Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE (2015) Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med 373(20):1937–1946. doi:10.1056/NEJMoa1505532

    Article  CAS  PubMed  Google Scholar 

  9. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, Mancini GB (2008) Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359(7):677–687. doi:10.1056/NEJMoa072771

    Article  CAS  PubMed  Google Scholar 

  10. Howard DH, Shen YC (2014) Trends in PCI volume after negative results from the COURAGE trial. Health Serv Res 49(1):153–170. doi:10.1111/1475-6773.12082

    Article  PubMed  Google Scholar 

  11. ISCHEMIA Trial (2016) Clinicaltrials.gov Database. International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) (2016). https://clinicaltrials.gov/ct2/show/NCT01471522. Accessed 11/13/2016

  12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  13. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47–53. doi:10.1001/jama.291.1.47

    Article  CAS  PubMed  Google Scholar 

  14. Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE (2016) Continuous combined estrogen plus progestin and endometrial cancer: the women’s health initiative randomized trial. J Natl Cancer Inst 108(3). doi:10.1093/jnci/djv350

  15. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD (2007) Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health (The Journal of the International Society for Pharmacoeconomics and Outcomes Research) 10(5):326–335. doi:10.1111/j.1524-4733.2007.00186.x

    Article  Google Scholar 

  16. Hutchins LF, Unger JM, Crowley JJ, Coltman CAJ, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067. doi:10.1056/NEJM199912303412706 http://www.nejm.org/doi/full/10.1056/NEJM199912303412706

    Article  CAS  PubMed  Google Scholar 

  17. Wasilewski J, Polonski L, Lekston A, Osadnik T, Regula R, Bujak K, Kurek A (2015) Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center. Trials 16:411. doi:10.1186/s13063-015-0934-4

    Article  PubMed  PubMed Central  Google Scholar 

  18. Downing NS, Shah ND, Neiman JH, Aminawung JA, Krumholz HM, Ross JS (2016) Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials 17:199. doi:10.1186/s13063-016-1322-4

    Article  PubMed  PubMed Central  Google Scholar 

  19. Berger ML, Harnett J (2017) Are real-world data and evidence good enough to inform health care and health policy decision making? In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  20. Bonney M, Birnbaum HG (2017) Perspectives on the use of comparative effectiveness research by life sciences executives: an interview with Mike Bonney. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  21. Cohen J, DiMasi J, Kaitin K (2017) Impact of comparative effectiveness research on drug development strategy and innovation. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  22. Frois C, Gueger J (2017) Pricing of pharmaceuticals: current trends and outlook, and the role of comparative effectiveness research. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  23. Willke RJ (2017) Translating CER evidence to real-world decision-making: some practical considerations. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  24. Piech CT, Lefebvre P, Pike CT (2017) Comparative effectiveness research: a pharmaceutical industry perspective on outlook, dilemmas, and controversies. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  25. Signorovitch J, Zhang J (2017) Indirect comparisons: a brief history and a practical look forward. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  26. Onukwugha E, Jain R, Albarmawi H (2017) Evidence generation using big data: challenges and opportunities. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  27. Dadson N, Pinheiro L, Royer J (2017) Decision-making with machine learning in our modern, Data-Rich Healthcare Industry. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  28. Rossiter LF (2017) Decision making by public payers. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  29. Xie J, Chalkidou K, Kamae I, Dittrich RE, Mahbub R, Vasan A, Metallo C (2017) Policy Considerations: Ex-U.S. Payers and Regulators. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  30. Lefebvre P, Lafeuille MH, Tiggelaar S (2017) Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH). In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness. Springer, Singapore

    Google Scholar 

  31. Hung A, Baas C, Bekelman J, Fitz-Randolph M, Mullins CD (2017) Patient and stakeholder engagement in designing pragmatic clinical trials. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  32. Gately ME, Schmitt PD (2017) Challenges and opportunities in the dissemination of comparative effective-ness research information to Physicians and payors: a legal perspective. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  33. Kalb P, Greenberg PE, Pike C (2017) Legal considerations in a world of comparative effectiveness research. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

  34. Asche CV, Hippler S, Eurich D (2017) Application of comparative effectiveness research to promote adherence to clinical practice guidelines. In: Birnbaum HG, Greenberg PE (eds) Decision making in a world of comparative effectiveness research. Springer, Singapore

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Analysis Group, Inc., Menlo Park, CA, USA

    Dave Nellesen

  2. Analysis Group, Inc., Boston, MA, USA

    Howard G. Birnbaum & Paul E. Greenberg

Authors
  1. Dave Nellesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard G. Birnbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul E. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dave Nellesen .

Editor information

Editors and Affiliations

  1. Analysis Group, Inc., Boston, Massachusetts, USA

    Howard G. Birnbaum

  2. Analysis Group, Inc., Boston, Massachusetts, USA

    Paul E. Greenberg

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Nellesen, D., Birnbaum, H.G., Greenberg, P.E. (2017). Perspectives of Comparative Effectiveness Research from the World of Decision Making. In: Birnbaum, H., Greenberg, P. (eds) Decision Making in a World of Comparative Effectiveness Research. Adis, Singapore. https://doi.org/10.1007/978-981-10-3262-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3262-2_2

  • Published:

  • Publisher Name: Adis, Singapore

  • Print ISBN: 978-981-10-3261-5

  • Online ISBN: 978-981-10-3262-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation